Provided by Tiger Trade Technology Pte. Ltd.

Fractional Shares

2,024.63
+8.590.43%
Number of Gainers:660
Number of Losers:345
Number of Flat:16
PE:- -
High:2,026.93
Open:2,016.07
Low:2,012.68
Close:2,016.04
Volume:5.21B
Turnover:655.27B
Market Cap:96.84T
Float Cap:90.58T

Loading ...

Best Buy, Amazon Expand Fire TV Partnership, Open Ad Inventory to Best Buy Ads

Reuters
·
Sep 23

Norway's Crude Output Recovery Needs Context Beyond the Base Effect

Deep News
·
Sep 23

Talisker Resources Begins Trading on OTCQX After Upgrade from OTCQB

Reuters
·
Sep 23

AC Immune Reports Positive Week-100 Safety, Immunogenicity in Phase 2 VacSYn Trial of Parkinson’s Vaccine ACI-7104

Reuters
·
Sep 23

Manchester United Q4 Adjusted Net Income GBP -28.2 Million

Reuters
·
Sep 23

General Mills Q1 Adj. EPS $0.75 Beats $0.72 Estimate, Sales $4.390B Beat $4.351B Estimate

Benzinga Earnings
·
Sep 23

Abbott and Berry Street Partner to Expand Personalized Nutrition Support for Consumers Seeking Better Metabolic Health

THOMSON REUTERS
·
Sep 23

Avalo Therapeutics to Present Phase 2 LOTUS Trial Results for Abdakibart in Hidradenitis Suppurativa at EADV 2026

Reuters
·
Sep 23

General Mills Outlook FY Net Sales Growth -1.5 to 0.5%

THOMSON REUTERS
·
Sep 23

General Mills Q1 Adjusted EPS USD 0.75 VS. Ibes Estimate USD 0.72

THOMSON REUTERS
·
Sep 23

General Mills Q1 Operating Profit USD 633.6 Million

THOMSON REUTERS
·
Sep 23

General Mills Q1 Adjusted Gross Margin 33.3%

THOMSON REUTERS
·
Sep 23

General Mills: Reaffirms Full-Year Outlook

THOMSON REUTERS
·
Sep 23

General Mills - Expects at Least $750 Mln in Cost Savings in Fiscal 2027

THOMSON REUTERS
·
Sep 23

General Mills: Expects Category Growth Below Long-Term Historical Growth Rate in Fy2027, Driven by Continued Challenging Consumer Backdrop

THOMSON REUTERS
·
Sep 23

Manchester United Outlook FY Adjusted Ebitda GBP 205-225 Million

THOMSON REUTERS
·
Sep 23

Manchester United Q4 Basic EPS GBP -0.1666

THOMSON REUTERS
·
Sep 23

Manchester United Plc Reports Fourth Quarter and Full Year Fiscal 2026 Results

THOMSON REUTERS
·
Sep 23

Immunovant Announces Topline Results from Proof-of-Concept Study of Imvt-1402 in Cutaneous Lupus Erythematosus

THOMSON REUTERS
·
Sep 23

Immunovant, - Imvt-1402 Study in Cle Did not Achieve Statistical Significance on Primary Endpoint

THOMSON REUTERS
·
Sep 23